AANP PMHNP Certification Board Exam | Ultimate Study Bank | 400
High-Yield Practice Questions & Answers with Detailed Rationales |
Psychiatric Assessment, Diagnosis, Psychopharmacology & Clinical
Management | Advanced Certification Review | Premium Exam
Mastery Guide
Question 1
A 32-year-old patient with treatment-resistant depression has been on multiple SSRIs without
adequate response. The PMHNP is considering augmentation strategies. Which neurotransmitter
system is primarily targeted by the addition of low-dose aripiprazole in this scenario?
A. Norepinephrine reuptake inhibition
B. Serotonin 5-HT2A receptor antagonism
C. Dopamine D2 receptor partial agonism
D. GABA-A receptor positive allosteric modulation
Correct Answer: C
Explanation: Aripiprazole acts as a partial agonist at dopamine D2 receptors, making it effective as an
augmentation agent in treatment-resistant depression. This mechanism stabilizes dopamine activity
while also affecting serotonin 5-HT1A partial agonism and 5-HT2A antagonism. Clinical pearl:
Aripiprazole's unique mechanism allows for improved efficacy with lower risk of extrapyramidal
symptoms compared to full D2 antagonists.
Question 2
A 45-year-old patient with bipolar I disorder is stabilized on lithium but complains of persistent
tremor and polyuria. The PMHNP recognizes these as dose-dependent side effects. Which mechanism
explains lithium's antimanic properties?
A. Inhibition of glycogen synthase kinase-3 (GSK-3)
,B. Blockade of voltage-gated sodium channels
C. Enhancement of GABA-mediated chloride influx
D. Antagonism of N-methyl-D-aspartate (NMDA) receptors
Correct Answer: A
Explanation: Lithium inhibits GSK-3 and inositol monophosphatase, affecting intracellular signaling
cascades and neurotransmitter release. This neuroprotective mechanism stabilizes mood by
modulating synaptic plasticity. Clinical pearl: Therapeutic lithium levels (0.6-1.2 mEq/L) require careful
monitoring due to narrow therapeutic index; tremor and polyuria are common dose-related effects.
Question 3
A 28-year-old patient with schizophrenia is started on paliperidone. The PMHNP explains that this
medication has a unique pharmacokinetic property compared to other atypical antipsychotics. What
distinguishes paliperidone's formulation?
A. It requires once-daily dosing due to enteric-coated formulation
B. It has a transdermal delivery system for sustained release
C. It utilizes an osmotic-controlled release oral delivery system (OROS)
D. It is only available as an immediate-release oral tablet
Correct Answer: C
Explanation: Paliperidone ER uses OROS technology, providing controlled drug release over 24 hours
with less peak-trough fluctuation. This improves tolerability and adherence compared to immediate-
release formulations. Clinical pearl: Paliperidone is the active metabolite of risperidone and may be
better tolerated in patients who experienced extrapyramidal symptoms with risperidone.
Question 4
A 19-year-old college student presents with acute-onset auditory hallucinations and disorganized
speech following 72 hours of sleep deprivation during final exams. The PMHNP suspects substance-
induced psychosis. Which neurotransmitter system is most implicated in the pathophysiology of both
schizophrenia and stimulant-induced psychosis?
,A. Serotonergic system dysregulation
B. Dopaminergic system hyperactivation
C. Glutamatergic system hypofunction
D. Cholinergic system overactivity
Correct Answer: B
Explanation: Both schizophrenia and stimulant-induced psychosis involve dopamine hyperactivity,
particularly in mesolimbic pathways. This explains why antipsychotics with dopamine D2 antagonism
are effective for both conditions. Clinical pearl: Sleep deprivation can transiently increase dopamine
release, potentially unmasking psychotic symptoms in vulnerable individuals.
Question 5
A 62-year-old patient with Parkinson's disease develops visual hallucinations and paranoid delusions.
The PMHNP is considering medication management. Which antipsychotic is preferred in this
population due to its minimal motor side effect profile?
A. Haloperidol
B. Quetiapine
C. Pimavanserin
D. Fluphenazine
Correct Answer: C
Explanation: Pimavanserin is a selective 5-HT2A inverse agonist approved specifically for Parkinson's
disease psychosis, with no D2 receptor affinity and minimal extrapyramidal side effects. Clinical pearl:
Parkinson's disease psychosis treatment requires balancing psychiatric symptoms with motor function
preservation; pimavanserin represents a paradigm shift in managing this challenging population.
Question 6
, A 55-year-old patient with generalized anxiety disorder is started on buspirone. The PMHNP counsels
the patient about the medication's mechanism of action. How does buspirone differ from
benzodiazepines in treating anxiety?
A. It has direct GABA-A receptor agonist properties
B. It acts as a partial agonist at 5-HT1A receptors
C. It inhibits serotonin reuptake in the synapse
D. It blocks norepinephrine alpha-2 receptors
Correct Answer: B
Explanation: Buspirone is a partial agonist at presynaptic and postsynaptic 5-HT1A receptors,
modulating serotonergic transmission without the sedation, tolerance, and dependence seen with
benzodiazepines. Clinical pearl: Buspirone requires 2-4 weeks for therapeutic effect and is less
effective for acute anxiety, making it more suitable for chronic GAD management.
Question 7
A 24-year-old patient with panic disorder is prescribed sertraline. The PMHNP explains the potential
for initial anxiety exacerbation. Which neurobiological mechanism explains this phenomenon?
A. Immediate GABA receptor downregulation
B. Increased serotonin availability at postsynaptic 5-HT2A receptors
C. Dopamine D2 receptor hypersensitivity
D. Norepinephrine transporter inhibition
Correct Answer: B
Explanation: Initial SSRI treatment increases serotonin at 5-HT2A receptors before autoreceptor
desensitization occurs, potentially worsening anxiety. This typically resolves within 2-3 weeks as 5-
HT1A autoreceptors downregulate. Clinical pearl: Starting at low doses and titrating slowly minimizes
initial anxiety exacerbation in panic disorder patients.
High-Yield Practice Questions & Answers with Detailed Rationales |
Psychiatric Assessment, Diagnosis, Psychopharmacology & Clinical
Management | Advanced Certification Review | Premium Exam
Mastery Guide
Question 1
A 32-year-old patient with treatment-resistant depression has been on multiple SSRIs without
adequate response. The PMHNP is considering augmentation strategies. Which neurotransmitter
system is primarily targeted by the addition of low-dose aripiprazole in this scenario?
A. Norepinephrine reuptake inhibition
B. Serotonin 5-HT2A receptor antagonism
C. Dopamine D2 receptor partial agonism
D. GABA-A receptor positive allosteric modulation
Correct Answer: C
Explanation: Aripiprazole acts as a partial agonist at dopamine D2 receptors, making it effective as an
augmentation agent in treatment-resistant depression. This mechanism stabilizes dopamine activity
while also affecting serotonin 5-HT1A partial agonism and 5-HT2A antagonism. Clinical pearl:
Aripiprazole's unique mechanism allows for improved efficacy with lower risk of extrapyramidal
symptoms compared to full D2 antagonists.
Question 2
A 45-year-old patient with bipolar I disorder is stabilized on lithium but complains of persistent
tremor and polyuria. The PMHNP recognizes these as dose-dependent side effects. Which mechanism
explains lithium's antimanic properties?
A. Inhibition of glycogen synthase kinase-3 (GSK-3)
,B. Blockade of voltage-gated sodium channels
C. Enhancement of GABA-mediated chloride influx
D. Antagonism of N-methyl-D-aspartate (NMDA) receptors
Correct Answer: A
Explanation: Lithium inhibits GSK-3 and inositol monophosphatase, affecting intracellular signaling
cascades and neurotransmitter release. This neuroprotective mechanism stabilizes mood by
modulating synaptic plasticity. Clinical pearl: Therapeutic lithium levels (0.6-1.2 mEq/L) require careful
monitoring due to narrow therapeutic index; tremor and polyuria are common dose-related effects.
Question 3
A 28-year-old patient with schizophrenia is started on paliperidone. The PMHNP explains that this
medication has a unique pharmacokinetic property compared to other atypical antipsychotics. What
distinguishes paliperidone's formulation?
A. It requires once-daily dosing due to enteric-coated formulation
B. It has a transdermal delivery system for sustained release
C. It utilizes an osmotic-controlled release oral delivery system (OROS)
D. It is only available as an immediate-release oral tablet
Correct Answer: C
Explanation: Paliperidone ER uses OROS technology, providing controlled drug release over 24 hours
with less peak-trough fluctuation. This improves tolerability and adherence compared to immediate-
release formulations. Clinical pearl: Paliperidone is the active metabolite of risperidone and may be
better tolerated in patients who experienced extrapyramidal symptoms with risperidone.
Question 4
A 19-year-old college student presents with acute-onset auditory hallucinations and disorganized
speech following 72 hours of sleep deprivation during final exams. The PMHNP suspects substance-
induced psychosis. Which neurotransmitter system is most implicated in the pathophysiology of both
schizophrenia and stimulant-induced psychosis?
,A. Serotonergic system dysregulation
B. Dopaminergic system hyperactivation
C. Glutamatergic system hypofunction
D. Cholinergic system overactivity
Correct Answer: B
Explanation: Both schizophrenia and stimulant-induced psychosis involve dopamine hyperactivity,
particularly in mesolimbic pathways. This explains why antipsychotics with dopamine D2 antagonism
are effective for both conditions. Clinical pearl: Sleep deprivation can transiently increase dopamine
release, potentially unmasking psychotic symptoms in vulnerable individuals.
Question 5
A 62-year-old patient with Parkinson's disease develops visual hallucinations and paranoid delusions.
The PMHNP is considering medication management. Which antipsychotic is preferred in this
population due to its minimal motor side effect profile?
A. Haloperidol
B. Quetiapine
C. Pimavanserin
D. Fluphenazine
Correct Answer: C
Explanation: Pimavanserin is a selective 5-HT2A inverse agonist approved specifically for Parkinson's
disease psychosis, with no D2 receptor affinity and minimal extrapyramidal side effects. Clinical pearl:
Parkinson's disease psychosis treatment requires balancing psychiatric symptoms with motor function
preservation; pimavanserin represents a paradigm shift in managing this challenging population.
Question 6
, A 55-year-old patient with generalized anxiety disorder is started on buspirone. The PMHNP counsels
the patient about the medication's mechanism of action. How does buspirone differ from
benzodiazepines in treating anxiety?
A. It has direct GABA-A receptor agonist properties
B. It acts as a partial agonist at 5-HT1A receptors
C. It inhibits serotonin reuptake in the synapse
D. It blocks norepinephrine alpha-2 receptors
Correct Answer: B
Explanation: Buspirone is a partial agonist at presynaptic and postsynaptic 5-HT1A receptors,
modulating serotonergic transmission without the sedation, tolerance, and dependence seen with
benzodiazepines. Clinical pearl: Buspirone requires 2-4 weeks for therapeutic effect and is less
effective for acute anxiety, making it more suitable for chronic GAD management.
Question 7
A 24-year-old patient with panic disorder is prescribed sertraline. The PMHNP explains the potential
for initial anxiety exacerbation. Which neurobiological mechanism explains this phenomenon?
A. Immediate GABA receptor downregulation
B. Increased serotonin availability at postsynaptic 5-HT2A receptors
C. Dopamine D2 receptor hypersensitivity
D. Norepinephrine transporter inhibition
Correct Answer: B
Explanation: Initial SSRI treatment increases serotonin at 5-HT2A receptors before autoreceptor
desensitization occurs, potentially worsening anxiety. This typically resolves within 2-3 weeks as 5-
HT1A autoreceptors downregulate. Clinical pearl: Starting at low doses and titrating slowly minimizes
initial anxiety exacerbation in panic disorder patients.
